Innovative
Therapeutics for
Better Health

Because Life
Shouldn't Have to
Wait for Migraines

Our Lead Product Candidate

STS101

Dihydroergotamine (DHE) Nasal Powder

Learn More

Clinical Trials

SUMMIT™ Trial

Currently Recruiting

Learn More

Clinical Trials

ASCEND™ Trial

Ongoing

Learn More

Press Releases

Sep 20, 2022

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

Read More

Sep 06, 2022

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Read More